Corporate team

Our 24-strong team boasts deep experience in RNA biology, bioinformatics analytics, neuro-translation and development.

Dr Madeleine Wakeling

COO

Mandy Cowling

EA, Office Manager and HR Lead

Dr Jan Thirkettle

CEO

Dr Andy Billinton

CSO

Our programmes

Huntington's Disease

ALS and Alzheimer's

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

Read more

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

Read more

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

Read more

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

Read more